Thyroid hormone (TH) acts through specific receptors (TRs), which are conditional transcription factors, to induce fibroblast growth factor 21 (FGF21), a peptide hormone that is usually induced by fasting and that influences lipid and carbohydrate metabolism via local hepatic and systemic endocrine effects. While TH and FGF21 display overlapping actions when administered, including reductions in serum lipids, according to the current models these hormones act independently in vivo. In this study, we examined mechanisms of regulation of FGF21 expression by TH and tested the possibility that FGF21 is required for induction of hepatic TH-responsive genes. We confirm that active TH (triiodothyronine (T 3 )) and the TRb-selective thyromimetic GC1 increase FGF21 transcript and peptide levels in mouse liver and that this effect requires TRb. T 3 also induces FGF21 in cultured hepatocytes and this effect involves direct actions of TRb1, which binds a TRE within intron 2 of FGF21. Gene expression profiles of WTand Fgf21-knockout mice are very similar, indicating that FGF21 is dispensable for the majority of hepatic T 3 gene responses. A small subset of genes displays diminished T 3 response in the absence of FGF21. However, most of these are not obviously directly involved in T 3 -dependent hepatic metabolic processes. Consistent with these results, T 3 -dependent effects on serum cholesterol are maintained in the Fgf21 K/K background and we observe no effect of the Fgf21-knockout background on serum triglycerides and glucose. Our findings indicate that T 3 regulates the genes involved in classical hepatic metabolic responses independently of FGF21.
Introduction
Fibroblast growth factor 21 (FGF21) is one of three endocrine FGFs that influence metabolic responses via a combination of local and systemic actions. FGF21 is induced by the nuclear hormone receptor peroxisome proliferator-activated receptor a (PPARa) under fasting conditions, and secreted FGF21 peptide exerts autocrine/ paracrine effects on liver, including regulation of genes involved in lipogenesis, lipolysis, and fatty acid oxidation, as well as additional endocrine effects on other tissues (Badman et al. 2007) . Administration of FGF21 to overweight and diabetic mice results in decreases in the levels of plasma triglycerides and glucose, and increases in both insulin sensitivity and thermogenesis associated with decreased body weight (Coskun et al. 2008 , Berglund et al. 2009 , Xu et al. 2009 ). Conversely, mice that lack FGF21 exhibit late-onset obesity. Thus, there is intense interest in FGF21 as a therapeutic for metabolic disorders, weight loss, and diabetes. Potentially adverse effects of FGF21 have also come to light. FGF21 is involved in integration of metabolism and bone turnover, raising the possibility that FGF21 could promote bone loss, and elevated FGF21 levels are associated with abnormal lipid profiles in coronary heart disease, raising concerns about cardiovascular events (Iglesias et al. 2012 , Wei et al. 2012 . Moreover, FGF21 levels become elevated in obesity and nonalcoholic fatty liver disease, indicating that serum FGF21 levels do not always correlate with an improved metabolic profile. Given these concerns, it is important to understand how to manage local production of FGF21 in desired target tissues and the consequences of changes in FGF21 concentrations.
Thyroid hormones (THs) act as master regulators of metabolism and there is evidence for interdependency of TH and FGF21 signaling pathways. TH receptors (TRa and TRb) are members of the nuclear hormone receptor family that regulate target genes in response to the main active form of TH, triiodothyronine (T 3 ). TRs usually work by binding DNA-response elements (TREs) in the proximal promoters of target genes as heterodimers with retinoid X receptors (RXRs) but can also regulate target genes via protein-protein interactions with heterologous transcription factors (Baxter & Webb 2009 , Lin et al. 2013 . T 3 induces FGF21 in mouse liver and, in this study, TRb selectively enhances FGF21 expression and promoter activity via interactions with PPARa bound to PPARa-response elements, but does not require PPARa to induce other T 3 -regulated genes (Adams et al. 2010) . In addition, FGF21 administration to mice reduces serum levels of the parental form of TH, thyroxine (T 4 ), and T 3 , implying mutual regulatory dependency of these signaling systems (Domouzoglou et al. 2014) . In spite of these potential relationships, key actions of FGF21 and TH appear largely independent (Domouzoglou et al. 2014) . Recent assessments of administration of TH to Fgf21-knockout mice have revealed no differences in serum lipids, the expression of selected T 3 -regulated genes in liver and brown adipose tissue, or overall energy expenditure. Conversely, FGF21 elicited similar alterations in serum lipids and gene expression in hypothyroid and euthyroid mice.
In this study, we set out to understand the mechanisms and downstream effects of TH-dependent changes in hepatic Fgf21 expression. We find that both T 3 and the TRb-selective thyromimetic GC1 act through TRb to directly induce FGF21 expression and that the Fgf21 locus harbors a functional TRE within intron 2. This finding added another layer of complexity to previous studies of T 3 regulation of FGF21 expression, which indicated that TRb works primarily through PPARa bound to the FGF21 promoter (Adams et al. 2010) . While patterns of hepatic T 3 responses are similar in WT and Fgf21-knockout mice, similar to previous studies of a subset of hepatic genes involved in lipid metabolism (Domouzoglou & Maratos-Flier 2011 , Domouzoglou et al. 2014 , we also find that optimal response of a small subset of hepatic TH-target genes requires Fgf21. These genes, however, are not obviously related to metabolic regulation and we find no changes in serum metabolic parameters in Fgf21-knockout mice. Thus, our data support the idea that hepatic effects of TH on gene regulation and metabolism are largely independent of Fgf21.
Materials and method

Mice
All animal experiments were approved by the Animal Care and Use Committee of Houston Methodist Hospital Research Institute. Mouse strains C57BL/6, ApoE K/K , Ldlr K/K , and TRb K/K were purchased from The Jackson Laboratory (Bar Harbor, ME, USA) at 9 weeks of age.
Fgf21
K/K mice on a C57/BL6 background were received from The University of Texas Southwestern Medical Center (Dallas, TX, USA). For short-term ligand treatments (1 and 3 days) T 3 , GC1, or vehicle (control) were administered to mice (nZ5) by oral gavage at a dose of 1 mg/kg body weight, after which, mice were killed and dissected for tissue harvesting. For long-term treatments (2 weeks), GC1 was admixed into diet at a dose of 0.8 mg/kg body weight, after which the mice were killed for collection of blood and tissue samples.
Quantitative RT-PCR
Total RNA was isolated from livers or cultured cells using the RNAeasy Kit (Qiagen) and reverse transcribed to cDNA using the ABI Reverse Transcription Kit according to the manufacturer's instructions. Gene transcript expression was measured by quantitative RT-PCR (qPCR) (Roche LightCycler 480 II), in 20 ml reactions that included cDNA (10 ng of initial RNA input), 900 nM of each primer, PCR-grade water, and 10 ml of 2! TaqMan Master Mix (Applied Biosystems). The transcript expression levels were normalized to peptidylprolyl isomerase A (PPIA) expression levels. Independent samples were prepared from five to six different mice per genotype or three separate cell culture seedings and analyzed in technical triplicates. Gene transcript abundance was assessed by the standard DDCp method and results were expressed as relative fold change compared with respective control group. Primer catalog numbers are available on request.
Serum FGF21 analyses
Mouse serum FGF21 concentrations were determined by ELISA (Phoenix Secretomics (Burlingame, CA, USA), PS001-01-EK-M-1), according to the manufacturer's protocol. Serum samples of six to seven mice from each treatment were analyzed.
Immunoblot analysis
One hundred micrograms of liver were homogenized in 1 ml homogenization buffer (10 mM Tris-HCl (pH 7.5), 5 mM EDTA, 150 mM NaCl, 30 mM sodium phosphate, 10% glycerol, 0.5% NP40) containing complete protease inhibitor cocktail (Roche) using a Polytron homogenizer. The homogenate was centrifuged at 14 000 g for 8 min at 4 8C and the supernatant collected for further analysis. The proteins were separated by SDS-PAGE, transferred to polyvinylidine difluoride membranes (Millipore, Billerica, MA, USA), and detected with primary FGF21 and b-actin (Sigma) antibodies at 1:1000 and 1:10 000 dilutions, respectively, and HRP-conjugated secondary antibody at 1:5000 dilution. Immunoreactive proteins were visualized using the ECL western blotting detection system (Amersham, RPN2106), and densitometry analysis was conducted with Scion Image v4.0.3.2 software.
Cell culture
HepG2 (ATCC, Bethesda, MD, USA) and HepG2-TRb (Lin et al. 2013 ) cells were grown in DMEM supplemented with 10% fetal bovine serum (FBS), 100 U/ml of penicillin, 0.1 g/l of streptomycin, and 4 mmol/l glutamine, under 95% air and 5% CO 2 at 37 8C. For cycloheximide (CHX) treatment, HepG2-TRb cells were maintained within 10% resin-stripped FBS-DMEM media for 24 h before treatment. The cells were pretreated with CHX at 10 mg/ml for 30 min, followed by 10 nM T 3 incubation for 6 h, after which RNA was collected using the RNAeasy Kit (Qiagen). For RNA interference assays, HepG2-TRb cells were plated in 10% resin-stripped FBS-DMEM media and grown to 50% confluency. The cells were transfected with PPARa ON-TARGET plus SMART pool or negative control siRNA (Dharmacon, Waltham, MA, USA) at a 50 nM final concentration, and 48 h later treated with 10 nM T 3 or bezofibrate for 6 h, after which RNA was collected using the RNAeasy Kit (Qiagen).
Chromatin immunoprecipitation
Chromatin immunoprecipitation (ChIP) was performed using the EZ ChIP Kits (Millipore) according to the manufacturer's instructions. Briefly, mice livers were homogenized with a hand-held homogenizer in PBS containing a broad-spectrum protease inhibitor cocktail and then cross-linked with 1% formaldehyde. The nuclei were collected by adding lysis buffer following cross-linkage, which was stopped through addition of glycine. The liver nuclear solution was sonicated with a Fisher 60 Sonic Dismembranator (Thermo Fisher Scientific, Waltham, MA, USA). The sonicated solution was incubated with anti-TRb polyclonal antibody or control rabbit IgG (Millipore) overnight with agitation at 4 8C. The TRb antibody used for ChIP has also been used for TRb ChIP studies of mouse cerebellum and liver (Dong et al. 2009 , Paquette et al. 2011 and was originally purchased from Affinity Bioreagents (Golden, CO, USA), but was later made available through Thermo Fisher Scientific and Pierce (Grand Island, NY, USA), as PA1-213A. We have used the same antibody for western blotting analysis of TRb expression in cell lines and mouse liver with appropriate controls for TRb specificity shown , Lammel Lindemann et al. 2014 . Antibody-bound chromatin was precipitated with protein G-conjugated agarose beads, washed with gradient stringent buffers, and eluted with the elution buffer provided with the kit. The isolated DNA was analyzed by qPCR analysis using oligonucleotides corresponding to the following regions of the FGF21 locus: Fgf21C715/C902, forward: 5'-CAGACTGGCCCTCA-GAGAAG-3', reverse: 5'-CTCTGCCTAGGTTGGCATTC-3'. Fgf21C3727/C3880 forward: 5'-CATGTGGATTCTGG-GATTTG-3', reverse: 5'-GACCAGGCTGGACTCAAGTT-3'.
Transient transfection
For cloning of Fgf21-luciferase reporters, a 339-bp fragment of Fgf21 intron 2 was PCR amplified from C57BL/6 mouse gDNA and cloned into the BglII and HindIII sites of pGL4-23. Positive clones were confirmed through sequencing. For luciferase assays, HepG2-TRb1 cells (2!10 5 cells/well) were seeded into six-well plates 12 h before transfection of 1 mg/well of Fgf21-luciferase reporter constructs and 0.1 mg/well of Renilla-luciferase control plasmid using Fugene 6 transfection reagent. Twentyfour hours post transfection, cells were incubated with 10 nM T 3 for another 24 h, after which luciferase activity was determined using the Promega Dual Luciferase Assay Kit following the manufacturer's instructions.
Electrophoretic mobility shift assay
Electrophoretic mobility shift assay (EMSA) was performed by incubating 32 P-labeled oligonucleotide probes with in vitro translated TRb and RXRa. The results were visualized by autoradiography. Competition assays were performed by adding 100! molar excess of either unlabeled oligonucleotide probes (specific competitor) or unlabeled mutant oligonucleotide probe (nonspecific competitor, mutated bases are indicated in each figure) .
Microarray analysis
Mouse WG-6 v2 whole-genome expression arrays were purchased from Illumina (San Diego, CA, USA), and cRNA synthesis and labeling were performed using Illumina TotalPrep-96 RNA Amplification Kit (Ambion, Austin, TX, USA), with the labeling in vitro transcription reaction performed at 37 8C for 14 h. Biotinylated cRNA samples were hybridized to arrays at 58 8C for 18 h according to the manufacturer's protocol. Arrays were scanned using BeadArray Reader (Illumina). Unmodified microarray data obtained from GenomeStudio were background-subtracted and quantile-normalized using the lumi package (Du et al. 2008) and analyzed with the limma package (Smyth 2005) within R (R Development Core Team 2010). All analysis was corrected for multiple hypotheses testing (Benjamini & Hochberg 1995) and effects were determined to be significant when there was a greater than or equal to twofold increase/decrease relative to the control and they had an adjusted P value !0.05. Raw microarray data sets have been deposited in the NCBI Gene Expression Omnibus (GEO) 
Data analysis and statistics
All values are expressed as meanGS.E.M. Statistical analyses were performed using GraphPad Prism Version 5.0 Software (GraphPad, Inc., San Diego, CA, USA). Data were analyzed by Student's t-test, Mann-Whitney U test, or one-way ANOVA, where P values !0.05 were considered to be statistically significant.
Serum metabolites
Serum aliquots were sent to the comparative pathology laboratory of Baylor College of Medicine (Houston, TX, USA) for serum chemistry analysis.
Results
T 3 and GC1 induce Fgf21 in liver in a TRb-dependent manner
We examined the effects of acute (24 h) treatment of male C57BL/6 mice with T 3 or the thyromimetic GC1 on hepatic Fgf21 expression. Fgf21 mRNA was induced by both ligands, an effect not observed for genes that encode other secreted hepatic factors (Fig. 1A) . Similar effects of TR ligands on Fgf21 expression were seen in two mouse models of dyslipidemia (ApoE K/K and Ldlr K/K ) (Fig. 1B ) and FGF21 induction was accompanied by increases in circulating FGF21 peptide in serum (Fig. 1C) . The selective thyromimetic GC1 also elicited increases in hepatic Fgf21 expression, which persisted for at least 2 weeks with continuous treatment (Fig. 1D ). Optimal hepatic T 3 induction of FGF21 required TRb, the predominant TR subtype in liver ( Fig. 2A and B) . Thus, T 3 acts primarily through TRb to induce hepatic Fgf21 expression.
TRb directly induces Fgf21 in cultured cells
To define the mechanisms of TH-dependent induction of hepatic Fgf21 expression, we examined the response of Fgf21 mRNA to T 3 or GC1 in human HepG2 cells that stably express TRb (Lin et al. 2013) . We observed induction of FGF21 following short-term treatment with either ligand (Fig. 3A) . This effect persisted over several time points (Fig. 3B and results not shown). A modest T 3 response was also observed in parental HepG2 cells after extended T 3 treatment (Fig. 3B) ; this delayed effect resembles the kinetics of T 3 induction of other bona fide hepatic TR-target genes in this cell type and is probably a consequence of low levels of TRb that are present in these cells (Yuan et al. 2012) . T 3 -dependent FGF21 induction exhibited classical dose dependence with maximal activation with 10 nM hormone (Fig. 3C) , implying that this T 3 effect was TR-dependent, and was maintained after pretreatment with the protein synthesis inhibitor CHX, implying a direct transcriptional effect of TR (Fig. 3D) . Interestingly, the effects of TRb on FGF21 expression were not absolutely dependent on PPARa in HepG2 (Fig. 3E) . Although induction of Fgf21 mRNA by the PPARa ligand bezofibrate was abrogated by a PPARa-specific siRNA that reduced PPARa transcript levels by 80% (inset), the T 3 response was unaffected.
A functional TRE in the Fgf21 second intron
To determine whether TRb might bind the Fgf21 locus independently of PPARa, we consulted a published ChIP-chip dataset and our own preliminary ChIP-Seq results. Results of recent studies have indicated the presence of an intronic TRb-binding peak within the Fgf21 locus in mouse cerebellum (Dong et al. 2009 ) and we later confirmed the existence of this peak in the data derived from our own ChIP-Seq analysis of TRb-binding events in HepG2 cells (Fig. 4A ) . We verified TRb binding at this location with conventional ChIP-PCR performed on human HepG2-TRb cells (Fig. 4B ) and on native mouse liver (Fig. 4C) . Cloned sequences corresponding to the second intron of human FGF21 conferred T 3 responsiveness upon a luciferase reporter (Fig. 5A ). There was no response to PPARa ligand (WY14643). Deletion mapping indicated that important T 3 -responsive elements lay between the intronic sequences C771 and C842 downstream of the Fgf21 transcriptional start site (Fig. 5B ). This region of the mouse gene harbored a degenerate nonconsensus TRE (DR-5) with one well conserved half site (AGGTCA; reverse strand TCCAGT) (Fig. 5C) . Mutation of the putative TRE blocked the responses to T 3 of the Fgf21-dependent luciferase reporter (Fig. 5D) . Furthermore, the putative TRE bound bacterially expressed TRb in EMSA and this interaction was abolished by mutation of the AGGTCA sequence or an excess of WT oligonucleotide (Fig. 5E ).
Altered hepatic T 3 -responses in Fgf21
K/K mice As T 3 induces FGF21 in liver, and secreted FGF21 peptide may exert autocrine/paracrine effects upon gene expression in hepatocytes, we determined whether T 3 regulated the same genes in the livers of WT and euthyroid Fgf21 K/K mice using Illumina BeadArray analysis. More than 500 gene transcripts displayed significant response (greater than or equal to twofold with and adjusted P value !0.05) to a 3-day T 3 treatment in WT mice, in accordance with previous studies. In general, T 3 -dependent gene regulation patterns were similar in both WT and Fgf21-knockout mice and the majority of T 3 responses differed by not more than 50% (black points located within the dotted lines that delimit a twofold difference between WT and Fgf21 K/K mice) (Fig. 6A ). We detected two clusters of genes with altered T 3 response in the Fgf21 K/K background (red points, outside of dotted delimiting lines). One group (Table 1, 31 genes) exhibited diminished T 3 -dependent activation in the Fgf21 K/K background, and the other altered group (Table 2, 23 genes) displayed diminished T 3 -dependent repression. These altered responses to T 3 were readily reproduced in independent high-throughput qRT-PCR experiments (Fig. 6B) . Examples of such genes with diminished responses to T 3 in the Fgf21-knockout mice include Dio1, Insig2, Cdkn1, and Glut1 (Fig. 6C , full gene names in Table 1 ). Genes that displayed similar levels of T 3 response in both strains include Cpne2, Rab34, Creld2, and Wfdc6, as identified in our previous studies (Lin et al. 2013) (Fig. 6D) . Thus, targeted ablation of Fgf21 in the mouse germ line did not result in the global inhibition of a large percentage of hepatic T 3 responses, but FGF21 was required for induction of a small subset of T 3 -regulated genes.
We could not perceive many obvious relationships between genes that display altered responses to T 3 in the Fgf21-knockout mice and canonical hepatic metabolic process regulated by TH (Tables 1, 2, and 3) . Results of ingenuity pathway analysis (IPA) indicated that the gene subsets that showed altered T 3 response in the Fgf21-knockout background might affect the action of vitamin C, the complement pathway, and other processes (Table 3 and results not shown). Similar biological functions were predicted through Genecodis analysis (Tabas-Madrid et al.
2012) (not shown). More directed queries in which we
utilized IPA function pathway analysis to probe for the association of defined hepatic metabolic pathways with the T 3 /FGF21-dependent gene subset revealed the connections of several members of this gene set with different aspects of lipid metabolism, amino acid metabolism, and carbohydrate metabolism (Table 4) . Inspection of these relationships did not allow us to generate many obvious predictions about the influences of these genes upon local hepatic and systemic metabolism (see 'Discussion'). Given that there were weak associations of the T 3 /FGF21-dependent gene set with classical T 3 -dependent hepatic metabolic pathways, we determined whether Fgf21-knockout influenced the levels of serum metabolites under the conditions of our experiment (Fig. 7) . Previously, treatment with T 3 and a thyromimetic has been shown to result in rapid reductions in serum cholesterol levels in WT mice , Lammel Lindemann et al. 2014 ). While we were able to reproduce this effect with short T 3 (Fig. 7A) , it was unaltered in the Fgf21-knockout background. No T 3 -or Fgf21-dependent changes in serum triglyceride or glucose levels were detected during the course of this treatment ( Fig. 7B and C) .
Discussion
PPARa-dependent induction of FGF21 is required for changes in expression of genes that are involved in the fasting response in liver, and secreted hepatic Fgf21 influences local hepatocyte metabolism and communicates information from liver to other tissues to coordinate fasting responses. Thus, FGF21 has attracted attention as a possible therapeutic to modulate metabolic disease. In this study, we verified previous observations which indicate that T 3 induces hepatic FGF21 production (Adams et al. 2010 , Domouzoglou et al. 2014 , and further dissected the mechanism of this effect and tested the possibility that FGF21 is required for T 3 -dependent changes in local hepatic T 3 responses. Our results therefore support the concept that T 3 and FGF21 signaling pathways exhibit mutual regulatory dependence, but function largely independently (Domouzoglou et al. 2014) . T 3 acts through TRb to directly induce FGF21 expression. We extended previous studies (Adams et al. 2010 , Domouzoglou et al. 2014 to show that sustained TR-dependent induction of FGF21 is elicited by a selective TRb modulator and is dependent on TRb. Furthermore, similar effects were also observed in a human liver cell line (HepG2), in which FGF21 induction was amplified in the presence of exogenous TRb1, and T 3 -dependent induction of FGF21 was also detectable in the presence of low endogenous levels of TRb1 in this cell type (Yuan et al. 2012) . Thus, the capacity for T 3 regulation of hepatic FGF21 production is conserved in humans and in cultured cells of hepatic origin. Finally, TR regulation of FGF21 exhibits an appropriate T 3 dose response and is not affected by the protein synthesis inhibitor CHX, implying a direct effect of T 3 through TRs. While TRs do not bind to the Fgf21 proximal promoter, the results of studies by our own group and others indicate that TREs are often located within introns or the 3 0 downstream region of target genes (Chatonnet et al. 2013 , Gagne et al. 2013 , Ramadoss et al. 2014 . We therefore searched published databases of TRE localization and noted that the mouse Fgf21 locus harbors a TR-binding site in intron 2. This binding site was first detected in a study of TR-binding events near of T 3 -target genes in cerebellum (Dong et al. 2009 ), which we later confirmed by our own genome wide assessment of TRb1-binding events that utilized an engineered human HepG2 cell line that expresses exogenous TRb1 . We verified TR localization with human and mouse intron 2 using traditional ChIP-PCR approaches in HepG2 and native mouse liver and identified a functional TRE in this region of the mouse gene. We therefore suggest that TRs act through this intronic TRE to activate FGF21 expression in HepG2 cells and that this effect is independent of PPARa signaling. While our results indicate that TR can bind to a functional TRE in FGF21 intron 2, we emphasize that they do not contradict the results of previous studies which indicate that TRs cooperate with PPARa to enhance FGF21 proximal promoter activity (Adams et al. 2010) . Unlike the FGF21 proximal promoter, the putative FGF21 intronic TRE does not respond to PPARa ligands. Furthermore, bezofibrate activation of the human FGF21 gene is abolished by PPARa knockdown in HepG2 cells, with the T 3 response unaffected by PPARa knockdown. Thus, T 3 can activate the FGF21 gene independently of PPARa. However, we also verified that TRb and PPARa cooperate to elicit additive increases in FGF21-promoter-dependent luciferase reporter activity in transient transfections (results not shown). In the light of this study (Adams et al. 2010 ) and other suggestions that TRs cooperate with PPARs to regulate gene expression (Lu & Cheng 2010) , we suspect that TRs bound to the downstream intronic TRE can communicate with PPARa to regulate FGF21 expression. This idea leads to the prediction that T 3 regulation of FGF21 could be influenced by changes in PPARa activity and it will be interesting to see whether dietary conditions or administration of PPARa ligands could alter the patterns of hepatic T 3 regulation of FGF21 or hepatic gene response in general.
As FGF21 acts in an autocrine/paracrine fashion to regulate hepatic target genes involved in metabolic responses (Inagaki et al. 2007) , we also tested the hypothesis that T 3 -dependent regulation of hepatic gene expression programs would require FGF21. Specifically, we used an unbiased approach to determine whether responses to T 3 of any hepatic genes was diminished or abrogated in a mouse strain with a targeted deletion of the Fgf21 gene locus. While T 3 regulates hundreds of genes in the livers of euthyroid mice, many with important roles in T 3 -regulation of metabolic responses, there were limited differences in T 3 response patterns in WT and Fgf21 K/K mice. During our studies, a group led by Maratos-Flier et al. examined T 3 regulation of metabolic parameters in Fgf21-knockout mice and the effects of administered FGF21 in hypothyroid and euthyroid mouse backgrounds (Domouzoglou et al. 2014) . Results of this study revealed that T 3 and FGF21-dependent effects upon serum and hepatic lipid levels, thermogenesis and energy metabolism, and selected T 3 and FGF21 target genes are almost completely independent of the other hormone signaling system. Our transcriptome-wide gene expression studies extend and lend further support to this idea, and moreover, our own investigation of the effects of FGF21 and T 3 upon the levels of serum metabolites confirms that T 3 -dependent reductions in total serum cholesterol are completely independent of FGF21.
We detected a small subset of hepatic genes that displayed diminished responses to T 3 in the Fgf21 K/K background. In principle, such genes could be indirect targets that lie downstream of the FGF21 peptide, or FGF21 could be a permissive factor for induction of direct TR targets, analogous to the hepatic PPARa/FGF21 feedforward loop established under fasting conditions in which FGF21 activation prolongs PPARa-dependent responses (Badman et al. 2007 , Inagaki et al. 2007 ). While we have not determined the mechanisms of these effects, we suspect that the latter mechanism is at play at least in regulation of Dio1, which contains bona fide TREs within its proximal promoter (Zhang et al. 1998) . Perhaps more surprising, however, was that T 3 /FGF21-dependent genes were associated with complement activation and the cell cycle and that many classical T 3 -regulated genes involved in cholesterol metabolism , Lammel Lindemann et al. 2014 , fatty acid synthesis, b-oxidation, and gluconeogenesis (Singh et al. 2013 , Suh et al. 2013 , Thakran et al. 2013 did not appear in this list. The significance of the dual T 3 /FGF21 dependency displayed by this gene subset is not clear and requires further investigation.
We recognize that the notion that T 3 and FGF21 regulate hepatic metabolic response independently of each other must remain qualified for several reasons. We analyzed T 3 -dependent changes in gene expression and serum lipid parameters after 72 h treatment. While this is long enough to obtain significant elevations of hepatic and serum FGF21 levels, it is possible that interactions between TR and FGF21-dependent pathways could emerge over longer treatment times. Furthermore, our studies were performed in euthyroid mice treated with T 3 and not hypothyroid mice. Thus, it is possible that some T 3 -and FGF21-responsive genes with key roles in metabolic response could be fully induced at T 3 concentrations observed in euthyroid mice (data shown in Lin et al. (2013) ). Arguing against these possibilities, however, is the failure of the Maratos-Flier group also to identify defects in TR-dependent changes in metabolic parameters and gene expression in FGF21 knockouts over time courses of more than 1 week and in hypothyroid mice with varying levels of T 3 (Domouzoglou et al. 2014) .
It also remains possible that some members of the T 3 /FGF21-responsive gene subset could exert hard to predict effects upon metabolic responses. We attempted a more exhaustive effort to define the association of the T 3 /FGF21-responsive gene subset with classical metabolic pathways and discovered possible association of genes with various aspects of lipid, amino acid, and carbohydrate metabolic pathways and insulin-dependent diabetes mellitus (Table 4) . For example, DIO1 encodes a product that catalyzes the conversion of T 4 to T 3 and therefore will alter local TH levels and, potentially, TR actions upon key genes involved in cholesterol metabolism. INSIG2 is an inhibitor of sterol response element-binding protein (SREBP) activation and changes in levels of this transcription factor could result in widespread secondary alterations in the expression patterns of genes that regulate lipid metabolism. While it is conceivable that altered cooperation of TH and FGF21 at these, and other, genes could ultimately result in changes in systemic cholesterol and lipid levels, such effects were not obvious over the course of our study (Fig. 7) . At present our results are most consistent with the notion that T 3 -dependent hepatic gene regulation patterns are largely independent of FGF21 signaling.
